sitagliptin (MK0431) — Competitive Intelligence Brief

sitagliptin (MK0431) (sitagliptin (MK0431)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 Diabetes Small molecule

Target snapshot

sitagliptin (MK0431) (sitagliptin (MK0431)) — Merck Sharp & Dohme LLC. Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which is involved in the inactivation of incretin hormones.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sitagliptin (MK0431) TARGET	sitagliptin (MK0431)	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor	DPP-4
Metformin plus vildagliptin	Metformin plus vildagliptin	Sheba Medical Center	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
MET + Vildagliptin Group	MET + Vildagliptin Group	Hospital de Clinicas de Porto Alegre	marketed	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
Januvia (sitagliptin)	Januvia (sitagliptin)	Zealand University Hospital	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
Dapagliflozin/Sitagliptin	Dapagliflozin/Sitagliptin	Boryung Pharmaceutical Co., Ltd	marketed	SGLT2 inhibitor / DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class